Skip to main content

17 - References

References

780 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 8 References

  1. National Institute for Health and Care Excellence. Chronic kidney disease: assessment and management NICE Guideline [NG203]. 2021 (last checked May 2024); https://www.nice.org.uk/guidance/ng203.
  2. Levey AS, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604–612.
  3. Tangri N, et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA 2011; 305:1553–1559.
  4. Brater DC. Measurement of renal function during drug development. Br J Clin Pharmacol 2002; 54:87–95.
  5. Chinnadurai R, et al. Impact of chronic kidney disease on the drugs eliminated predominantly through a non-­renal route: a proof of concept study with citalopram. Nephrol Dial Transplant 2019; 34:gfz103.SP268.
  6. Toprak O, et al. New-­onset type II diabetes mellitus, hyperosmolar non-­ketotic coma, rhabdomyolysis and acute renal failure in a patient treated with sulpiride. Nephrol Dial Transplant 2005; 20:662–663.
  7. Baumgart U, et al. Olanzapine-­induced acute rhabdomyolysis—­a case report. Pharmacopsychiatry 2005; 38:36–37.
  8. Marsh SJ, et al. Rhabdomyolysis and acute renal failure during high-­dose haloperidol therapy. Ren Fail 1995; 17:475–478.
  9. Smith RP, et al. Quetiapine overdose and severe rhabdomyolysis. J Clin Psychopharmacol 2004; 24:343.
  10. Nagler EV, et al. Antidepressants for depression in stage 3–5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrol Dial Transplant 2012; 27:3736–3745.
  11. Palmer SC, et al. Antidepressants for treating depression in adults with end-­stage kidney disease treated with dialysis. Cochrane Database Syst Rev 2016; 5:CD004541.
  12. Dev V, et al. Higher anti-­depressant dose and major adverse outcomes in moderate chronic kidney disease: a retrospective population-­based study. BMC Nephrol 2014; 15:79.
  13. Guirguis A, et al. Antidepressant usage in haemodialysis patients: evidence of sub-­optimal practice patterns. J Ren Care 2020; 46:124–132.
  14. Farrokhi F, et al. Association between depression and mortality in patients receiving long-­term dialysis: a systematic review and meta-­analysis. Am J Kidney Dis 2014; 63:623–635.
  15. Lopes AA, et al. Depression as a predictor of mortality and hospitalization among hemodialysis patients in the United States and Europe. Kidney Int 2002; 62:199–207.
  16. Wu PH, et al. Depression amongst patients commencing maintenance dialysis is associated with increased risk of death and severe infections: a nationwide cohort study. PLoS One 2019; 14:e0218335.
  17. Saglimbene V, et  al. Depression and all-­cause and cardiovascular mortality in patients on haemodialysis: a multinational cohort study. Nephrol Dial Transplant 2017; 32:377–384.
  18. Natale P, et al. Psychosocial interventions for preventing and treating depression in dialysis patients. Cochrane Database Syst Rev 2019; 12:CD004542.
  19. Vangala C, et al. Selective serotonin reuptake inhibitor use and hip fracture risk among patients on hemodialysis. Am J Kidney Dis 2020; 75:351–360.
  20. Tzeng NS, et al. Is schizophrenia associated with an increased risk of chronic kidney disease? A nationwide matched-­cohort study. BMJ Open 2015; 5:e006777.
  21. Kessing LV, et al. Use of lithium and anticonvulsants and the rate of chronic kidney disease: a nationwide population-­based study. JAMA Psychiatry 2015; 72:1182–1191.
  22. Jiang Y, et al. A retrospective cohort study of acute kidney injury risk associated with antipsychotics. CNS Drugs 2017; 31:319–326.
  23. Ryan PB, et al. Atypical antipsychotics and the risks of acute kidney injury and related outcomes among older adults: a replication analysis and an evaluation of adapted confounding control strategies. Drugs Aging 2017; 34:211–219.
  24. IBM Watson Health. IBM Micromedex solutions. 2024 (accessed May 2024); https://www.ibm.com/watson-­health/about/micromedex.
  25. EMC. Summaries of product characteristics. 2024; https://www.medicines.org.uk/emc.
  26. Noble S, et al. Amisulpride: a review of its clinical potential in dysthymia. CNS Drugs 1999; 12:471–483.
  27. Taylor & Francis Group. Renal drug database. 2024 (accessed May 2024); https://renaldrugdatabase.com.
  28. Li A, et al. Population pharmacokinetics of amisulpride in Chinese patients with schizophrenia with external validation: the impact of renal function. Front Pharmacol 2023; 14:1215065.
  29. Aragona M. Tolerability and efficacy of aripiprazole in a case of psychotic anorexia nervosa comorbid with epilepsy and chronic renal failure. Eat Weight Disord 2007; 12:e54–e57.
  30. Mallikaarjun S, et  al. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole. Clin Pharmacokinet 2008; 47:533–542.
  31. Tzeng NS, et  al. Delusional parasitosis in a patient with brain atrophy and renal failure treated with aripiprazole: case report. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:1148–1149.
  32. De Donatis D, et al. Serum aripiprazole concentrations prehemodialysis and posthemodialysis in a schizophrenic patient with chronic renal failure: a case report. J Clin Psychopharmacol 2020; 40:200–202.
  33. Peeters P, et al. Asenapine pharmacokinetics in hepatic and renal impairment. Clin Pharmacokinet 2011; 50:471–481.
  34. Merative US L.P. Micromedex. 2024 (accessed May 2024); https://www.micromedexsolutions.com/home/dispatch.
  35. Fabre J, et al. Influence of renal insufficiency on the excretion of chloroquine, phenobarbital, phenothiazines and methacycline. Helv Med Acta 1967; 33:307–316.
  36. Aronoff GR, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th edn. Philadelphia: American College of Physicians; 2007.
  37. Fraser D, et al. An unexpected and serious complication of treatment with the atypical antipsychotic drug clozapine. Clin Nephrol 2000; 54:78–80.
  38. Au AF, et al. Clozapine-­induced acute interstitial nephritis. Am J Psychiatry 2004; 161:1501.

Prescribing in hepatic and renal impairment CHAPTER 8 39. Elias TJ, et al. Clozapine-­induced acute interstitial nephritis. Lancet 1999; 354:1180–1181. 40. Siddiqui BK, et al. Simultaneous allergic interstitial nephritis and cardiomyopathy in a patient on clozapine. NDT Plus 2008; 1:55–56. 41. Davis EAK, et al. Clozapine-­associated renal failure: a case report and literature review. Ment Health Clin 2019; 9:124–127. 42. Lim AM, et al. Clozapine, immunosuppressants and renal transplantation. Asian J Psychiatr 2016; 23:118. 43. Lobeck F, et  al. Haloperidol concentrations in an elderly patient with moderate chronic renal failure. J Geriatric Drug Ther 1986; 1:91–97. 44. Cohen LM, et al. Update on psychotropic medication use in renal disease. Psychosomatics 2004; 45:34–48. 45. Lendac Data Systems Ltd. Drugdex systems. 2024 (accessed May 2024); https://www.drugdiscoveryonline.com/doc/drugdex-­system-­0001. 46. Intra-­Cellular Therapies Inc. Highlights of prescribing information. Caplyta (lumateperone) capsules for oral use. 2019 (last accessed May 2024); https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf. 47. Kansagra A, et al. Prolonged hypothermia due to olanzapine in the setting of renal failure: a case report and review of the literature. Ther Adv Psychopharmacol 2013; 3:335–339. 48. Samalin L, et al. Interest of clozapine and paliperidone palmitate plasma concentrations to monitor treatment in schizophrenic patients on chronic hemodialysis. Schizophr Res 2015; 166:351–352. 49. Lin JH, et al. Long-­acting injectable paliperidone palmitate in a haemodialysis patient with schizophrenia. Aust NZ J Psychiatry 2021; 55:829–830. 50. ACADIA Pharmaceuticals Inc. Highlights of prescribing information. Nuplazid (pimavanserin) tablets for oral use. 2016 (last accessed May 2024); https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf. 51. Thyrum PT, et al. Single-­dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment. Prog Neuropsychopharmacol Biol Psychiatry 2000; 24:521–533. 52. Huynh M, et al. Thrombotic thrombocytopenic purpura associated with quetiapine. Ann Pharmacother 2005; 39:1346–1348. 53. Torroba Sanz B, et al. Permanent renal sequelae secondary to drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by quetiapine. Eur J Hosp Pharm 2020; 5:285–288. 54. Snoeck E, et al. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology (Berl) 1995; 122:223–229. 55. Herguner S, et  al. Steroid-­induced psychosis in an adolescent: treatment and prophylaxis with risperidone. Turk J Pediatr 2006; 48:244–247. 56. Batalla A, et  al. Antipsychotic treatment in a patient with schizophrenia undergoing hemodialysis. J Clin Psychopharmacol 2010; 30:92–94. 57. Tourtellotte R, et al. Use of therapeutic drug monitoring of risperidone microspheres long-­acting injection in hemodialysis: a case report. Ment Health Clin 2019; 9:404–407. 58. Bressolle F, et al. Pharmacokinetics of sulpiride after intravenous administration in patients with impaired renal function. Clin Pharmacokinet 1989; 17:367–373. 59. Aweeka F, et al. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. Br J Clin Pharmacol 2000; 49:27S–33S. 60. Roerig. Highlights of prescribing information: GEODON® (ziprasidone HCl) capsules; GEODON® (ziprasidone mesylate) injection for intramuscular use. 2021 (last accessed May 2024); http://labeling.pfizer.com/ShowLabeling.aspx?id=584. 61. Iskandar JW, et al. Transient agranulocytosis associated with ziprasidone in a 45-­year-­old man on hemodialysis. J Clin Psychopharmacol 2015; 35:347–348. 62. Lieberman JA, et al. Tricyclic antidepressant and metabolite levels in chronic renal failure. Clin Pharmacol Ther 1985; 37:301–307. 63. Murphy EJ. Acute pain management pharmacology for the patient with concurrent renal or hepatic disease. Anaesth Intensive Care 2005; 33:311–322. 64. Chen TY, et al. Amitriptyline-­induced acute kidney injury and acute hepatitis: a case report. Am J Ther 2021; 28:e256–e258. 65. Sage Therapeutics Inc. Highlights of prescribing information. Zulresso (brexanolone) injection for intravenous use [controlled substance schedule pending]. 2019 (last checked May 2024); https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211371lbl.pdf. 66. Turpeinen M, et al. Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites. Br J Clin Pharmacol 2007; 64:165–173. 67. Worrall SP, et al. Pharmacokinetics of bupropion and its metabolites in haemodialysis patients who smoke. A single dose study. Nephron Clin Pract 2004; 97:c83–c89. 68. Ghoreishi A, et  al. Bupropion as a treatment for sexual dysfunction among chronic kidney disease patients. Acta Med Iran 2019; 57:320–327. 69. Joffe P, et al. Single-­dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. Eur J Clin Pharmacol 1998; 54:237–242. 70. Kalender B, et al. Antidepressant treatment increases quality of life in patients with chronic renal failure. Ren Fail 2007; 29:817–822. 71. Kelly CA, et  al. Adult respiratory distress syndrome and renal failure associated with citalopram overdose. Hum Exp Toxicol 2003; 22:103–105. 72. Spigset O, et al. Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis. Eur J Clin Pharmacol 2000; 56:699–703. 73. Hosseini SH, et al. Citalopram versus psychological training for depression and anxiety symptoms in hemodialysis patients. Iran J Kidney Dis 2012; 6:446–451. 74. Sran H, et al. Confusion after starting citalopram in a renal transplant patient. BMJ Case Rep 2013; 2013:bcr2013010511. 75. Assimon MM, et  al. Comparative cardiac safety of selective serotonin reuptake inhibitors among individuals receiving maintenance ­hemodialysis. J Am Soc Nephrol 2019; 30:611–623.

782 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 8 76. Assimon MM, et al. Proton pump inhibitors may enhance the risk of citalopram-­ and escitalopram-­associated sudden cardiac death among patients receiving hemodialysis. Pharmacoepidemiol Drug Saf 2022; 31:670–679. 77. Assimon MM, et  al. The modifying effect of the serum-­to-­dialysate potassium gradient on the cardiovascular safety of SSRIs in the ­hemodialysis population: a pharmacoepidemiologic study. Nephrol Dial Transplant 2022; 37:2241–2252. 78. Onishi A, et  al. Reversible acute renal failure associated with clomipramine-­induced interstitial nephritis. Clin Exp Nephrol 2007; 11:241–243. 79. Wyeth Pharmaceuticals Inc. Highlights of prescribing information. PRISTIQ® (desvenlafaxine) extended-­release tablets, for oral use. 2023 (last checked May 2024); http://labeling.pfizer.com/showlabeling.aspx?id=497%20. 80. Nichols AI, et al. The pharmacokinetics and safety of desvenlafaxine in subjects with chronic renal impairment. Int J Clin Pharmacol Ther 2011; 49:3–13. 81. Rees JA. Clinical interpretation of pharmacokinetic data on dothiepin hydrochloride (Dosulepin, Prothiaden). J Int Med Res 1981; 9:98–102. 82. Swarna SS, et al. Pruritus associated with chronic kidney disease: a comprehensive literature review. Cureus 2019; 11:e5256. 83. Lobo ED, et al. Effects of varying degrees of renal impairment on the pharmacokinetics of duloxetine: analysis of a single-­dose phase I study and pooled steady-­state data from phase II/III trials. Clin Pharmacokinet 2010; 49:311–321. 84. Ho NV, et al. Duloxetine-­induced multi-­system organ failure: a case report. Poster presented at American Geriatrics Society Annual Meeting, May 11–15, 2011, National Harbor, Maryland; 2011. 85. Nguyen T, et al. Duloxetine uses in patients with kidney disease: different recommendations from the United States versus Europe and Canada. Am J Ther 2019; 26:e516–e519. 86. Uong C, et al. Poster 91. Serotonin syndrome in chronic kidney disease patient after given a dose of duloxetine while on trazodone: a case report. PM&R 2014; 6 Suppl:S214–S215. 87. Miriyala K, et al. Renal failure in a depressed adolescent on escitalopram. J Child Adolesc Psychopharmacol 2008; 18:405–408. 88. Adiga GU, et al. Renal tubular defects from antidepressant use in an older adult: an uncommon but reversible adverse drug effect. Clin Drug Invest 2006; 26:607–610. 89. Yazici AE, et al. Efficacy and tolerability of escitalopram in depressed patients with end stage renal disease: an open placebo-­controlled study. Bull Clin Psychopharmacol 2012; 22:23–30. 90. Bergstrom RF, et al. The effects of renal and hepatic disease on the pharmacokinetics, renal tolerance, and risk-­benefit profile of fluoxetine. Int Clin Psychopharmacol 1993; 8:261–266. 91. Blumenfield M, et al. Fluoxetine in depressed patients on dialysis. Int J Psychiatry Med 1997; 27:71–80. 92. Levy NB, et al. Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function. Gen Hosp Psychiatry 1996; 18:8–13. 93. Kauffman KM, et al. Higher dose weekly fluoxetine in hemodialysis patients: a case series report. Int J Psychiatry Med 2021; 56:3–13. 94. Constantino JL, et  al. Pharmacokinetics of antidepressants in patients undergoing hemodialysis: a narrative literature review. Braz J Psychiatry 2019; 41:441–446. 95. Lancaster SG, et al. Lofepramine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1989; 37:123–140. 96. Davis MP, et al. Mirtazapine for pruritus. J Pain Symptom Manage 2003; 25:288–291. 97. Fawaz B, et al. Defining the role of mirtazapine in the treatment of refractory pruritus. J Dermatolog Treat 2021; 32:132–136. 98. Liles AM, et al. Appetite stimulants for treatment of protein energy wasting of chronic kidney disease. Nephrol Nurs J 2021; 48:267–273. 99. Shibata K, et al. SP704 The effect of mirtazapine in dialysis patient with appetite loss. Nephrol Dial Transplant 2015; 30 Suppl 3:iii611. 100. Schoerlin MP, et al. Disposition kinetics of moclobemide, a new MAO-­A inhibitor, in subjects with impaired renal function. J Clin Pharmacol 1990; 30:272–284. 101. Stoeckel K, et al. Absorption and disposition of moclobemide in patients with advanced age or reduced liver or kidney function. Acta Psychiatr Scand Suppl 1990; 360:94–97. 102. Pollock BG, et  al. Metabolic and physiologic consequences of nortriptyline treatment in the elderly. Psychopharmacol Bull 1994; 30:145–150. 103. Doyle GD, et al. The pharmacokinetics of paroxetine in renal impairment. Acta Psychiatr Scand Suppl 1989; 350:89–90. 104. Ishii T, et al. A rare case of combined syndrome of inappropriate antidiuretic hormone secretion and Fanconi syndrome in an elderly woman. Am J Kidney Dis 2006; 48:155–158. 105. Kaye CM, et al. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand Suppl 1989; 350:60–75. 106. Koo JR, et  al. Treatment of depression and effect of antidepression treatment on nutritional status in chronic hemodialysis patients. Am J Med Sci 2005; 329:1–5. 107. Coulomb F, et al. Pharmacokinetics of single-­dose reboxetine in volunteers with renal insufficiency. J Clin Pharmacol 2000; 40:482–487. 108. Dostert P, et  al. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropsychopharmacol 1997; 7 Suppl 1:S23–S35. 109. Brewster UC, et  al. Addition of sertraline to other therapies to reduce dialysis-­associated hypotension. Nephrology (Carlton) 2003; 8:296–301. 110. Chan KY, et  al. Use of sertraline for antihistamine-­refractory uremic pruritus in renal palliative care patients. J Palliat Med 2013; 16:966–970. 111. Chander WP, et al. Serotonin syndrome in maintenance haemodialysis patients following sertraline treatment for depression. J Indian Med Assoc 2011; 109:36–37. 112. Jain N, et al. Rationale and design of the Chronic Kidney Disease Antidepressant Sertraline Trial (CAST). Contemp Clin Trials 2013; 34:136–144.

Prescribing in hepatic and renal impairment CHAPTER 8 113. Hedayati SS, et al. Effect of sertraline on depressive symptoms in patients with chronic kidney disease without dialysis dependence: the CAST randomized clinical trial. JAMA 2017; 318:1876–1890. 114. Razeghi E, et al. A randomized crossover clinical trial of sertraline for intradialytic hypotension. Iran J Kidney Dis 2015; 9:323–330. 115. Elsayed MM, et  al. The effectiveness of sertraline in alleviating uremic pruritus in hemodialysis patients: a randomized clinical trial. BMC Nephrol 2023; 24:155. 116. Mehrotra R, et al. Comparative efficacy of therapies for treatment of depression for patients undergoing maintenance hemodialysis: a randomized clinical trial. Ann Intern Med 2019; 170:369–379. 117. Friedli K, et al. Sertraline versus placebo in patients with major depressive disorder undergoing hemodialysis: a randomized, controlled feasibility trial. Clin J Am Soc Nephrol 2017; 12:280–286. 118. Chien CW, et al. Sertraline-­induced neutropenia and fatigue in a patient with end-­stage renal disease. Am J Ther 2020; 29:e101–e103. 119. Zahed NS, et al. Impact of sertraline on serum concentration of CRP in hemodialysis patients with depression. J Ren Injury Prevent 2017; 6:65–69. 120. Gregg LP, et al. Inflammation and response to sertraline treatment in patients with CKD and major depression. Am J Kidney Dis 2020; 75:457–460. 121. Catanese B, et al. A comparative study of trazodone serum concentrations in patients with normal or impaired renal function. Boll Chim Farm 1978; 117:424–427. 122. Mehrotra R, et al. Effectiveness of existing insomnia therapies for patients undergoing hemodialysis: a randomized clinical trial. Ann Intern Med 2024; 177:177–188. 123. Liao CY, et al. Taking sleeping pills and the risk of chronic kidney disease: a nationwide population-­based retrospective cohort study. Front Pharmacol 2021; 11:524113. 124. Leighton JD, et al. Trimipramine-­induced acute renal failure (Letter). NZ Med J 1986; 99:248. 125. Simpson GM, et al. A preliminary study of trimipramine in chronic schizophrenia. Curr Ther Res Clin Exp 1966; 99:248. 126. Troy SM, et al. The effect of renal disease on the disposition of venlafaxine. Clin Pharmacol Ther 1994; 56:14–21. 127. Guldiken S, et al. Complete relief of pain in acute painful diabetic neuropathy of rapid glycaemic control (insulin neuritis) with venlafaxine HCL. Diabetes Nutr Metab 2004; 17:247–249. 128. Pascale P, et al. Severe rhabdomyolysis following venlafaxine overdose. Ther Drug Monit 2005; 27:562–564. 129. Ren J, et al. Venlafaxine-­associated rhabdomyolysis: a literature review. J Clin Psychopharmacol 2024; 44:297–301. 130. Takeda Pharmaceuticals America Inc. Highlights of prescribing information. BRINTELLIX (vortioxetine) tablets 2023 (last accessed May 2024); www.us.brintellix.com. 131. Hegarty J, et al. Carbamazepine-­induced acute granulomatous interstitial nephritis. Clin Nephrol 2002; 57:310–313. 132. Tutor-­Crespo MJ, et al. Relative proportions of serum carbamazepine and its pharmacologically active 10,11-­epoxy derivative: effect of polytherapy and renal insufficiency. Ups J Med Sci 2008; 113:171–180. 133. Verrotti A, et al. Renal tubular function in patients receiving anticonvulsant therapy: a long-­term study. Epilepsia 2000; 41:1432–1435. 134. Hung CC, et al. Acute renal failure and its risk factors in Stevens-­Johnson syndrome and toxic epidermal necrolysis. Am J Nephrol 2009; 29:633–638. 135. Fervenza FC, et  al. Acute granulomatous interstitial nephritis and colitis in anticonvulsant hypersensitivity syndrome associated with ­lamotrigine treatment. Am J Kidney Dis 2000; 36:1034–1040. 136. Fillastre JP, et al. Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis. Drugs Exp Clin Res 1993; 19:25–32. 137. Schaub JE, et al. Multisystem adverse reaction to lamotrigine. Lancet 1994; 344:481. 138. Wootton R, et al. Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers. Br J Clin Pharmacol 1997; 43:23–27. 139. Bansal AD, et  al. Use of antiepileptic drugs in patients with chronic kidney disease and end stage renal disease. Semin Dial 2015; 28:404–412. 140. Gitlin M. Lithium and the kidney: an updated review. Drug Saf 1999; 20:231–243. 141. Lepkifker E, et al. Renal insufficiency in long-­term lithium treatment. J Clin Psychiatry 2004; 65:850–856. 142. Schoretsanitis G, et al. Prevalence of impaired kidney function in patients with long-­term lithium treatment: a systematic review and meta-­ analysis. Bipolar Disord 2022; 24:264–274. 143. McKnight RF, et al. Lithium toxicity profile: a systematic review and meta-­analysis. Lancet 2012; 379:721–728. 144. Shine B, et  al. Long-­term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data. Lancet 2015; 386:461–468. 145. Clos S, et al. Long-­term effect of lithium maintenance therapy on estimated glomerular filtration rate in patients with affective disorders: a population-­based cohort study. Lancet Psychiatry 2015; 2:1075–1083. 146. Kessing LV, et al. Lithium versus anticonvulsants and the risk of physical disorders – results from a comprehensive long-­term nation-­wide population-­based study emulating a target trial. Eur Neuropsychopharmacol 2024; 84:48–56. 147. Bosi A, et al. Absolute and relative risks of kidney outcomes associated with lithium vs valproate use in Sweden. JAMA Network Open 2023; 6:e2322056. 148. Schoot TS, et al. Systematic review and practical guideline for the prevention and management of the renal side effects of lithium therapy. Eur Neuropsychopharmacol 2020; 31:16–32. 149. Davis J, et al. Lithium and nephrotoxicity: a literature review of approaches to clinical management and risk stratification. BMC Nephrol 2018; 19:305. 150. Kuiper WJ, et al. Concurrent lithium and haemodialysis treatment: clinical recommendations based on the literature and a multicentre survey. Bipolar Disord 2024; 26:335–347.

784 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 8 151. Smith GC, et al. Anticonvulsants as a cause of Fanconi syndrome. Nephrol Dial Transplant 1995; 10:543–545. 152. Fukuda Y, et al. Immunologically mediated chronic tubulo-­interstitial nephritis caused by valproate therapy. Nephron 1996; 72:328–329. 153. Watanabe T, et al. Secondary renal Fanconi syndrome caused by valproate therapy. Pediatr Nephrol 2005; 20:814–817. 154. Tanaka H, et al. Distal type of renal tubular acidosis after anti-­epileptic therapy in a girl with infantile spasms. Clin Exp Nephrol 1999; 3:311–313. 155. Rahman MH, et al. Acute hemolysis with acute renal failure in a patient with valproic acid poisoning treated with charcoal hemoperfusion. Hemodial Int 2006; 10:256–259. 156. Koga S, et al. Risk factors for sodium valproate-­induced renal tubular dysfunction. Clin Exp Nephrol 2018; 22:420–425. 157. Hayes JF, et al. Adverse renal, endocrine, hepatic, and metabolic events during maintenance mood stabilizer treatment for bipolar disorder: a population-­based cohort study. PLoS Med 2016; 13:e1002058. 158. Damba JJ, et al. Psychotropic drugs and adverse kidney effects: a systematic review of the past decade of research. CNS Drugs 2022; 36:1049–1077. 159. Kessing LV, et al. Continuation of lithium after a diagnosis of chronic kidney disease. Acta Psychiatr Scand 2017; 136:615–622. 160. Pentikainen PJ, et al. Pharmacokinetics of chlormethiazole in healthy volunteers and patients with cirrhosis of the liver. Eur J Clin Pharmacol 1980; 17:275–284. 161. Dashti-­Khavidaki S, et al. Comparing effects of clonazepam and zolpidem on sleep quality of patients on maintenance hemodialysis. Iran J Kidney Dis 2011; 5:404–409. 162. Sadjadi SA, et al. Allergic interstitial nephritis due to diazepam. Arch Intern Med 1987; 147:579. 163. Sunovion Pharmaceuticals Inc. Highlights of prescribing information. LUNESTA® (eszopiclone) tablets, for oral use. 2014 (last accessed May 2024); https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf. 164. Blum RA, et  al. Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clin Pharmacol Ther 1994; 56:154–159. 165. Miller A, et al. Gabapentin toxicity in renal failure: the importance of dose adjustment. Pain Med 2009; 10:190–192. 166. Upjohn UK Limited. Summary of product characteristics. Neurontin (gabapentin) 600mg film-­coated tablets. 2023 (last accessed May 2024); https://www.medicines.org.uk/emc/product/3197/smpc. 167. Yeddi A, et al. Myoclonus and altered mental status induced by single dose of gabapentin in a patient with end-­stage renal disease: a case report and literature review. Am J Ther 2019; 26:e768–e770. 168. Ishida JH, et al. Gabapentin and pregabalin use and association with adverse outcomes among hemodialysis patients. J Am Soc Nephrol 2018; 29:1970–1978. 169. Gobo-­Oliveira M, et al. Gabapentin versus dexchlorpheniramine as treatment for uremic pruritus: a randomised controlled trial. Eur J Dermatol 2018; 28:488–495. 170. Gunal AI, et al. Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-­controlled, double-­blind trial. Nephrol Dial Transplant 2004; 19:3137–3139. 171. Beladi Mousavi SS, et al. The effect of gabapentin on muscle cramps during hemodialysis: a double-­blind clinical trial. Saudi J Kidney Dis Transpl 2015; 26:1142–1148. 172. Razazian N, et al. Gabapentin versus levodopa-­c for the treatment of restless legs syndrome in hemodialysis patients: a randomized clinical trial. Saudi J Kidney Dis Transpl 2015; 26:271–278. 173. Rossi GM, et  al. Randomized trial of two after-­dialysis gabapentin regimens for severe uremic pruritus in hemodialysis patients. Intern Emerg Med 2019; 14:1341–1346. 174. Eisai Inc. Highlights of prescribing information. Dayvigo (lemborexant) tablets for oral use [controlled substance schedule pending]. 2019 (last accessed May 2024); https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf. 175. Landry I, et al. Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant. Pharmacol Res Perspect 2021; 9:e00734. 176. Huang CE, et al. Intramuscular lorazepam in catatonia in patients with acute renal failure: a report of two cases. Chang Gung Med J 2010; 33:106–109. 177. Reynolds HN, et al. Hyperlactatemia, increased osmolar gap, and renal dysfunction during continuous lorazepam infusion. Crit Care Med 2000; 28:1631–1634. 178. Verbeeck RK, et al. Impaired elimination of lorazepam following subchronic administration in two patients with renal failure. Br J Clin Pharmacol 1981; 12:749–751. 179. Yaucher NE, et al. Propylene glycol-­associated renal toxicity from lorazepam infusion. Pharmacotherapy 2003; 23:1094–1099. 180. Zar T, et al. Acute kidney injury, hyperosmolality and metabolic acidosis associated with lorazepam. Nat Clin Pract Nephrol 2007; 3:515–520. 181. Hayman M, et al. Acute tubular necrosis associated with propylene glycol from concomitant administration of intravenous lorazepam and trimethoprim-­sulfamethoxazole. Pharmacotherapy 2003; 23:1190–1194. 182. Mastroianni G, et al. Management of status epilepticus in patients with liver or kidney disease: a narrative review. Expert Rev Neurother 2021; 21:1251–1264. 183. Markowska M, et al. Melatonin treatment in kidney diseases. Cells 2023; 12:838. 184. Yang J, et  al. Effects of melatonin against acute kidney injury: a systematic review and meta-­analysis. Int Immunopharmacol 2023; 120:110372. 185. Aperis G, et al. The role of melatonin in patients with chronic kidney disease undergoing haemodialysis. J Ren Care 2012; 38:86–92. 186. Russcher M, et al. The role of melatonin treatment in chronic kidney disease. Front Biosci (Landmark Ed) 2012; 17:2644–2656. 187. Upjohn UK Limited. Lyrica (pregabalin) 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg hard capsules. 2024 (last accessed May 2024); https://www.medicines.org.uk/emc/product/10303/smpc.

Prescribing in hepatic and renal impairment CHAPTER 8 188. Desai A, et al. Gabapentin or pregabalin induced myoclonus: a case series and literature review. J Clin Neurosci 2019; 61:225–234. 189. Du YT, et  al. Seizure induced by sudden cessation of pregabalin in a patient with chronic kidney disease. BMJ Case Rep 2017; 2017:bcr2016219158. 190. Foroutan N, et al. Comparison of pregabalin with doxepin in the management of uremic pruritus: a randomized single blind clinical trial. Hemodial Int 2017; 21:63–71. 191. Otsuki T, et al. Efficacy and safety of pregabalin for the treatment of neuropathic pain in patients undergoing hemodialysis. Clin Drug Investig 2017; 37:95–102. 192. Khan NJ, et al. Comparing the efficacy and safety of pregabalin vs gabapentin in uremic pruritus in patients of chronic kidney injury ­undergoing haemodialysis. J Ayub Med Coll Abbottabad 2022; 34:524–527. 193. Safarpour Y, et al. Restless legs syndrome in chronic kidney disease – a systematic review. Tremor Other Hyperkinet Mov (NY) 2023; 13:10. 194. Murray TG, et al. Renal disease, age, and oxazepam kinetics. Clin Pharmacol Ther 1981; 30:805–809. 195. Leung N, et al. Acute kidney injury in patients with inactive cytochrome P450 polymorphisms. Ren Fail 2009; 31:749–752. 196. Drover DR. Comparative pharmacokinetics and pharmacodynamics of short-­acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin Pharmacokinet 2004; 43:227–238. 197. Rehman IU, et al. Effectiveness and safety profiling of zolpidem and acupressure in CKD associated pruritus: an interventional study. Medicine (Baltimore) 2021; 100:e25995. 198. Hsu FG, et  al. Use of zolpidem and risk of acute pyelonephritis in women: a population-­based case-­control study in Taiwan. J Clin Pharmacol 2017; 57:376–381. 199. Goa KL, et al. Zopiclone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic. Drugs 1986; 32:48–65. 200. Hussain N, et al. Zopiclone-­induced acute interstitial nephritis. Am J Kidney Dis 2003; 41:E17. 201. Suwata J, et al. New acetylcholinesterase inhibitor (donepezil) treatment for Alzheimer’s disease in a chronic dialysis patient. Nephron 2002; 91:330–332. 202. Nagy CF, et al. Steady-­state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. Br J Clin Pharmacol 2004; 58 Suppl 1:18–24. 203. Tiseo PJ, et al. An evaluation of the pharmacokinetics of donepezil HCl in patients with moderately to severely impaired renal function. Br J Clin Pharmacol 1998; 46 Suppl 1:56–60. 204. Sahin OZ, et al. A rare case of acute renal failure secondary to rhabdomyolysis probably induced by donepezil. Case Rep Nephrol 2014; 2014:214359. 205. Wang HM, et al. Letter to the editor: Donepezil-­induced parkinsonism in end-­stage renal disease. Neurol Sci 2021; 42:4809–4812. 206. Periclou A, et al. Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clin Pharmacol Ther 2006; 79:134–143. 207. Prasad P, et al. Memantine induced encephalopathy in chronic kidney disease: a case report. Postgrad Med J 2023; 99:498–499. 208. Lefevre G, et al. Effects of renal impairment on steady-­state plasma concentrations of rivastigmine: a population pharmacokinetic analysis of capsule and patch formulations in patients with Alzheimer’s disease. Drugs Aging 2016; 33:725–736. 209. AMAG Pharmaceutical Inc. Highlights of prescribing information. Vyleesi (bremelanotide injection) for subcutaneous use. 2019 (last accessed May 2024); https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf. 210. Nelson ME, et al. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clin Toxicol (Phila) 2012; 50:1169–1173. 211. Teva Pharmaceuticals USA Inc. Highlights of prescribing information. Austedo (deutetrabenazine) tablets for oral use. 2017 (last accessed May 2024); https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209885lbl.pdf. 212. Lincoln Medical Limited. Wakix 4.5mg/18mg film-­coated tablets. 2023 (last accessed May 2024); https://www.medicines.org.uk/emc/ product/7402. 213. Bioprojet Pharma. Highlights of prescribing information. Wakix (pitolisant) tablets for oral use. 2019 (last accessed May 2024); https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211150s000lbl.pdf. 214. Atnahs Pharma UK Ltd. Sunosi (solriamfetol) 75mg and 140mg film-­coated tablets. 2023 (last accessed May 2024); https://www.medicines. org.uk/emc/product/14978/pil#gref. 215. Zomorodi K, et al. Single-­dose pharmacokinetics and safety of solriamfetol in participants with normal or impaired renal function and with end-­stage renal disease requiring hemodialysis. J Clin Pharmacol 2019; 59:1120–1129. 216. Genus Pharmaceuticals. Summary of product characteristics. Atomoxetine 40  mg hard capsules. 2020 (last accessed April 2024); https://www.medicines.org.uk/emc/product/11126/smpc. 217. Medice UK Ltd. Summary of product characteristics. Amfexa 5mg, 10mg, 20mg tablets. 2023 (last accessed May 2024); https://www.­ medicines.org.uk/emc/search?q=amfexa. 218. Takeda UK Limited. Summary of product characteristics. Elvanse 20mg, 30mg, 40mg, 50mg, 60mg and 70mg capsules, hard (lisdexafetamine). 2023 (last accessed May 2024); https://www.medicines.org.uk/emc/product/14091/smpc. 219. Ermer J, et al. A single-­dose, open-­label study of the pharmacokinetics, safety, and tolerability of lisdexamfetamine dimesylate in individuals with normal and impaired renal function. Ther Drug Monit 2016; 38:546–555. 220. Janssen-­Cilag Ltd. Summary of product characteristics. Concerta XL 18  mg, 27  mg, 36  mg, 54  mg prolonged-­release tablets. 2023 (last accessed April 2024); https://www.medicines.org.uk/emc/product/6872/smpc. 221. Stiebel VG. Methylphenidate plasma levels in depressed patients with renal failure. Psychosomatics 1994; 35:498–500. 222. Kasahara S, et al. Case report: guanfacine and methylphenidate improved chronic lower back pain in autosomal dominant polycystic kidney disease with comorbid attention deficit hyperactivity disorder and autism spectrum disorder. Front Pediatr 2023; 11:1283823. 223. Gregg LP, et al. Pharmacologic and psychological interventions for depression treatment in patients with kidney disease. Curr Opin Nephrol Hypertens 2020; 29:457–464.

No comments to display

Back to top